- Now a pure-play R&D company
- Has three breakthrough technologies
- Two drugs in clinical trials
What the company does
R&D company Midatech is developing a range of improved chemo-therapies and new immuno-therapeutics using its three drug delivery platforms. Each of the technologies is focused on improved delivery and distribution of medicines to areas of the body where they are needed and can exert their actions in an effective, safe and precise manner.
Q-Sphera is a polymer microsphere innovation used to prolong and control the release of therapeutics over an extended period of time -from weeks to months.
MidaCore is the company’s gold nanoparticle product used for targeting sites of disease at the nanoscale, usually chemotherapy, but also the new breed of immunotherapies.
MidaSolve is used to dissolve otherwise insoluble drugs so they can be administered in liquid form directly and locally into tumours.
It has three drugs in or entering the clinic treating carcinoid cancer, acromegaly (a hormonal disorder), brain cancer in children, and type-1 auto-immune diabetes (see below).
Last month Midatech said it had begun a “new chapter” where it is aiming to provide investors with two years packed with news flow. After selling its US commercial business late last year, the company is now fully focused on developing its drugs pipeline, with the company’s two lead drugs in human clinical trials.
With MTD201 (Q-Sphera technology) has taken an existing drug for acromegaly and improved its efficiency and precision. After an early-phase clinical trial it must decide whether to pursue a differentiated product with a distinct clinical profile compared with the existing medication, or to establish an interchangeable alternative to it. Midatech expects to finalise that decision soon, ahead of the next clinical programme set for the second-half of this year. If this is successful, MDT201 could be submitted for marketing authorisation in 2021.
MTX110 (MidaSolve). A read-out from a phase I dose-escalating and safety study on children with brain cancer is expected sometime this year. “Results to date have been encouraging and show that the therapy is well tolerated,” the company said recently. “This phase will also establish the recommended dose to be used in the follow-on phase II efficacy component of the study programme, with the objective of assessing patient survival rates after 12 months. It would be wonderful to make a difference to patients and families dealing with this shattering disease.”
In March firm said the Spanish government had conditionally approved a €6.6mln Reindustrialisation, or Reindus loan that will be used to help commercialise its flagship drug. In all, the group has received around €8.5mln of public backing towards the estimated €16mln costs to build a plant in Bilbao to manufacture its MTD201 Q-Octreotide development product. Chief executive Craig Cook said the Reindus loan would provide “a real boost” to the commercial manufacturing scale-up scheduled over the next 18-24 months in Bilbao.
Chief executive Craig Cook said…
"2018 was a year of strategic refocusing of the business, with Midatech becoming a pure-play R&D company following the divestment of our US commercial operation in November, a major milestone for the group. We believe the company has entered a new chapter in its growth as a streamlined R&D focused business with in-house manufacturing. We are now delivering on clinical milestones, with strong clinical data, and a compelling pipeline for our proprietary drug delivery platforms, all of which are now into the clinic.”